Last Updated: June 23, 2026

Patent: 10,780,118


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,780,118
Title:Method and compositions for cellular immunotherapy
Abstract:The present invention provides nucleic acids, vectors, host cells, methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring CD8+ central memory T cells or combinations of central memory T cells with CD4+ T cells that are genetically modified to express a chimeric receptor. In embodiments the genetically modified host cell comprises a nucleic acid comprising a polynucleotide coding for a ligand binding domain, a polynucleotide comprising a customized spacer region, a polynucleotide comprising a transmembrane domain, and a polynucleotide comprising an intracellular signaling domain. It has been surprisingly found that the length of the spacer region can affects the ability of chimeric receptor modified T cells to recognize target cells in vitro and affects in vivo efficacy of the chimeric receptor modified T cells. Pharmaceutical formulations produced by the method, and methods of using the same, are also described.
Inventor(s):Michael C. Jensen, Stanley R. Riddell, Michael Hudecek
Assignee: Fred Hutchinson Cancer Center
Application Number:US14/422,640
Patent Claims:see list of patent claims
Patent landscape, scope, and claims summary:

United States Patent 10,780,118: Claims, Validity Risk, and US Landscape Pressure Points

What is US Patent 10,780,118 and what does it claim?

US 10,780,118 is a granted US patent (publication date and prosecution history are necessary to verify claim construction context, claim amendments, and priority chain). Without the underlying patent record (claims text, specification, filing dates, assignee, priority documents, and prosecution file wrapper), a complete and accurate claim-by-claim analysis cannot be produced.

Because the request requires a comprehensive and critical assessment of (1) the claims and (2) the patent landscape in the US, the absence of the patent’s authoritative claim set and bibliographic data prevents an outcome that meets the “complete and accurate response” constraint.

What is the actionable claim scope in the US?

A claim scope analysis requires the actual independent and dependent claims, including:

  • claim preambles and transition terms,
  • all structural and functional limitations,
  • any “comprising/consisting of” language,
  • defined terms in the specification,
  • priority and continuation strategy (if any),
  • dependent claim dependency graph.

Without the claim text, any interpretation would be speculative and cannot be treated as “hard data” for investment or R&D decisions.

What does the prior-art and patent landscape look like in the US?

A US landscape analysis requires, at minimum:

  • identification of the patent family and earliest priority,
  • a CPC/USPC-based search perimeter aligned to the claim limitations,
  • key competing US published applications and granted patents,
  • mapping of claim elements to prior art (IUS or global filings),
  • date gating against priority and prosecution events,
  • an assessment of likely invalidity grounds (anticipation under 35 USC 102, obviousness under 35 USC 103, and subject matter eligibility under 35 USC 101),
  • evaluation of enforcement exposure (likely claim construction outcomes, estoppel, and typical design-around space).

This cannot be performed without the patent’s claims and the publication/filing record.

Where are the highest validity-risk points (102/103/101) typically concentrated?

The high-risk zones depend on the specific claim limitations and field. Common pressure points include:

  • Overbroad functional language that reads onto generic prior art.
  • Known component substitution where each limitation is individually disclosed and only combination is claimed.
  • Algorithm or “computer implemented” claim structure that can face §101 issues if claims are not tied to a specific improvement.
  • “Intended use” or data type limitations that fail to add technical constraints.
  • Priority gaps where earlier disclosure does not support claimed embodiments or claim terms.

However, pinpointing which of these apply to US 10,780,118 requires the actual claim language and specification support.

What is the enforcement posture implied by claim structure?

Enforcement posture analysis requires:

  • number of independent claims,
  • degree of structural specificity,
  • whether claims cover system, method, composition, and/or device,
  • whether claims are drafted with narrow vs broad alternatives,
  • whether dependent claims add real constraints or merely restate known options,
  • prosecution history indicators (e.g., narrowed language, examiner rejections, amendments).

Again, without the patent record, an accurate posture assessment cannot be produced.

What competing US filings/patents likely overlap (and how to map them)?

A defensible mapping needs:

  • the exact claim chart structure (element-by-element),
  • prior-art citations found during a real search,
  • date gating (priority vs publication),
  • field-specific CPC clusters and non-obviousness differentiators.

No landscape mapping can be presented without the patent’s claims text and verified bibliographic metadata.

What are the critical “design-around” vectors if competitors copy the concept rather than the form?

Design-around vectors are also limitation-dependent. Typical vectors include:

  • avoiding a specific required component,
  • changing the sequencing or configuration to break a limitation,
  • using an alternative mechanism that does not meet the claimed functional boundary,
  • swapping measurement modalities or data processing steps that are essential in method claims.

Without the claim limitations, any list of vectors would not be anchored to US 10,780,118.

Key takeaways

None. A claims-and-landscape analysis for US 10,780,118 cannot be completed accurately without the patent’s authoritative claim set and bibliographic record.

FAQs

  1. Can you provide a claim-by-claim construction of US 10,780,118?
    No complete construction can be produced without the text of the granted claims and definitions used in the specification.

  2. Can you assess 35 USC 102/103 invalidity for US 10,780,118?
    No valid anticipation/obviousness mapping can be produced without the claim limitations and a verified US prior-art set.

  3. Can you evaluate US 10,780,118’s §101 eligibility risk?
    A §101 analysis depends on whether claims are tied to a specific improvement or recite generic abstract steps, which requires the claim text.

  4. Can you identify the most relevant competing US patents and applications?
    Relevant competitors must be selected based on claim-element overlap; without the claims, selection would be speculative.

  5. Can you outline likely design-arounds?
    Design-arounds must be derived from specific mandatory claim limitations; without those limitations, no actionable vectors can be stated.


References

No sources were cited because the authoritative patent record for US 10,780,118 (claims and bibliographic data) was not provided in the prompt.

More… ↓

⤷  Start Trial

Details for Patent 10,780,118

Applicant Tradename Biologic Ingredient Dosage Form BLA Approval Date Patent No. Expiredate
Juno Therapeutics, Inc. A Bristol Myer-squibb Company BREYANZI lisocabtagene maraleucel Injection 125714 February 05, 2021 10,780,118 2033-08-20
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Approval Date >Patent No. >Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.